Female "Viagra" - Lybrido & Lybridos - two new drugs for Female Sexual Dysfunction (FSD)

About 43% of adult women suffer from Female Sexual Dysfunction (FSD). Low sexual desire, with or without sexual arousal problems, is the most common sex related complaint reported by women. As a result, many women suffer from sexual dissatisfaction, which often negatively interferes with psychological and social wellbeing. This has been classified as a clinical condition, referred to as Hypoactive Sexual Desire Disorder (HSDD). This condition is widespread, it is considered by many an unmet medical need.

There is no FDA-approved drug for (subtypes of) FSD and no effective diagnostic tool to differentiate between the main types of FSD, although more than 80% of physicians agree that there is a (great) need for an FDA-approved therapy for FSD.

Different causal mechanisms are responsible for female sexual complaints. In the HSDD subgroup of FSD patients, sexual complaints occur either as the result of a relatively insensitive system for sexual cues (low desire) or as a result of maladaptive sexual inhibitory mechanisms.

Different Causal Mechanisms for HSDD: Different Treatments

Based on the assumption that different causal mechanisms are responsible for the same symptoms in HSDD, we started a drug development program for two subgroups of women. In one subgroup of women sexual dysfunction occurs as the result of a relatively insensitive system for sexual cues. In another subgroup of patients the sexual complaints result from maladaptive sexual inhibitory mechanisms.

Lybrido (working title) has been developed for patients with HSDD and a relatively insensitive system for sexual cues. 

Lybridos (working title) has been developed for women with HSDD and maladaptive sexual inhibitory mechanisms.

Both drug candidates can be taken ‘on demand’ and help to increase central sexual motivation (libido) about 3 to 6 hours after intake.

Moreover, we have developed an algorithm (simple, practical and useable), partly based on genetics, by which a differentiation can be made between Lybrido and Lybridos responders.

http://www.emotionalbrain.nl